Login| Sign Up| Help| Contact|

Patent Searching and Data


Matches 301 - 350 out of 17,604

Document Document Title
WO/2018/107236A1
The present disclosure relates to antibacterial compounds. In particular, the compounds are for inhibiting the growth of bacteria, particularly Mycobacterium tuberculosis (Mtb), and/or targeting bacteria having phospho-MurNAc-pentapeptid...  
WO/2018/104537A1
A 3D structure of a hydrogel for supporting cell growth or for use in sustained drug delivery is formed using peptides and/or peptide derivatives that self- assemble via cross-linking into a stiff gel. The hydrogel structure is formed us...  
WO/2018/104962A1
The invention pertains to the synthesis, isolation, and characterization of hemiaminal for selective labeling of peptides, proteins, antibodies, and organic fragments with -C(=0) CH2NH2 and derivatives with -CH2NH2 group over -C(=0) CHRN...  
WO/2018/098571A1
It is provided a tumor promoting alternative splicing isoform of PACE4, named PACE4-alt CT, analytes specifically binding to PACE4-alt CT, such as antibodies, and use of same for detecting a cancer, such as prostate cancer. It is also pr...  
WO/2018/102536A1
Methods for enhancing the immune response and/or treatment of diseases such as cancer comprising an agent that specifically binds TIGIT are disclosed. The TIGIT-binding agents may include polypeptides, antibodies, and/or bispecific agents.  
WO/2018/097741A1
Peptidomimetic analogs suitable for use in cancer therapy, or as antagonists of opioid drugs, and suitable application of the compounds are disclosed. The described compounds display cytostatic and cytotoxic effects toward intestinal can...  
WO/2018/095422A1
Provided in the present invention are a di-substituted maleic amide linker conjugated to an antibody and a preparation method and use thereof. In particular, the present invention conjugates a strongly cytotoxic active substance to a bio...  
WO/2018/093449A1
A self-assembling peptide is provided that is enzymatically oxidized to form a polymeric pigment. The monomeric peptide has three amino acids (tyrosine (Y), one phenylalanine (F), and one aspartic acid (D) or one lysine (K)) and, followi...  
WO/2018/081897A1
CD47+ disease cells such as cancer cells are treated using a combination of CD47 blockade drug and a proteasome inhibitor. The anti-cancer effect of one drug enhances the 5 anti-cancer effect of the other. Specific combinations include S...  
WO/2018/085836A1
The present disclosure provides simple β-hairpin peptides in linear and cyclic form that specifically bind to HIV-1 Trans-Activation Response element (HIV-1 TAR), as well as compositions and use thereof.  
WO/2018/081898A1
CD47+ disease cells such as cancer cells are treated using a combination of CD47 blockade drug and a histone deacetylase (HDAC) inhibitor. The anti-cancer effect of one drug enhances the anti-cancer effect of the other. Specific combinat...  
WO/2018/085415A1
Integrin ligands having serum stability and affinity for ανβ6 integrins are described. Compositions comprising ανβ6 integrin ligands having serum stability and having affinity for ανβ6 integrins and methods of using them are als...  
WO/2018/079859A1
This cell labeling method is characterized in that a complex, which has acquired membrane affinity as a result of reacting a substrate complex, in which hydrophilic groups are bonded to fluorescent groups, or conjugates of fluorescent gr...  
WO/2018/080349A1
The invention relates to peptide chemistry, pharmacology, and medicine, and specifically to a new group of peptides having the property of stimulating sexual and genital function and having increased storage stability. For this purpose, ...  
WO/2018/075885A1
Supramolecular structures comprising noncovalently associated peptide amphiphiles and lipids are provided. In particular, provided herein are supramolecular nanostructures of peptide amphiphiles and lipids, co-assembly of which is driven...  
WO/2018/072689A1
The present invention provides a stachydrine derivative, a preparation method therefor, and applications thereof in the preparation of drugs for treating cardiovascular and cerebrovascular diseases. The stachydrine derivative is a compon...  
WO/2018/071640A1
The invention relates to a peptide of formula (I) R1-Wm-Xn-AA1-AA2-AA3-Yp-Zq-R2, cosmetic or pharmaceutical compositions comprising same and its use, for example, in the reduction of lipid accumulation in the skin, the treatment of cellu...  
WO/2018/070829A1
The present invention relates to an expression cassette for preparing a copper peptide and use thereof, and more specifically, to an expression cassette for preparing a copper peptide comprising a polynucleotide sequence encoding a pepti...  
WO/2018/071556A1
Provided are methods of identifying, visualizing and purifying proteases from a complex biological sample.  
WO/2018/071761A1
A mitochondrial-targeted PARP inhibitor is provided herein, as well as methods of making and using the mitochondrial-targeted PARP inhibitor.  
WO/2018/066545A1
Provided is a drug that can decompose a target intracellular protein specifically and is effective for the prevention or treatment of diseases associated with the target protein. An SNIPER compound produced by linking a specific IAP liga...  
WO/2018/066914A1
The present invention relates to a tripeptide having fatty acids bonded thereto and a cosmetic composition comprising same and provides excellent skin anti-aging, wrinkle reduction, skin elasticity enhancement, and skin permeation effects.  
WO/2018/067457A1
An apparatus and method for performing analysis and identification of molecules have been presented. In one embodiment, a portable molecule analyzer includes a sample input/output connection to receive a sample, a nanopore-based sequenci...  
WO/2018/052949A1
The present disclosure provides compounds represented by Formula I: I, and the pharmaceutically acceptable salts, hydrates, and solvates thereof, wherein R1, R2a, R2b, R3, R4, Ar, L, X, Y, and B are as defined as set forth in the specifi...  
WO/2018/053109A1
This invention provides a process tor characterizing a glatiramer acetate related drug substance - or drug product comprising the steps of: (a) obtaining a batch of the glatiramer acetate related drag substance or drug product; (b) conta...  
WO/2018/053049A1
Provided herein are polynucleic acids and expression vectors for the expression and secretion of angiotensin peptide fragments (e.g., angiotensin-(1-7)) in probiotic bacteria. Provided herein are also probiotic compositions that enable e...  
WO/2018/053135A1
The present disclosure provides a novel sweetener composition of improved taste of the sweetener (e.g., reduced bitterness and/or astringency, and improved overall sweet quality of the composition); food and beverage products containing ...  
WO/2018/050663A1
The present invention relates to novel compounds which effectively inhibit the melanin synthesis in human melanocytes and are thus suitable for the treatment of senile lentigines, for smoothening skin color irregularities and/or for ligh...  
WO/2018/044012A1
The present invention relates to a peptide having anticancer activity, and a cancer preventing and treating pharmaceutical composition, functional health food composition and functional cosmetic composition containing same as an active i...  
WO/2018/036942A1
The invention provides novel compounds having the general formula (I): (I) wherein R1, R2, R3, R4, R5, R6, R7, R8, A, X and R11 are as described herein, compositions including the compounds and methods of using the compounds.  
WO/2018/035610A1
The present invention provides 18F-labeled amino acids or derivatives thereof having formula (I) and methods of making same, which can be suitable for PET imaging: (Formula (I)).  
WO/2018/035519A1
The present invention relates to compositions and methods for the treatment or prevention of autoimmune diseases such as demyelination disorders. The invention includes a composition comprising a peptide antigen comprising at least one b...  
WO/2018/034356A1
The present invention provides a peptide comprising an amino acid sequence represented by any of formulas (I)-(III), and a conjugate comprising the peptide and a functional part. (I) The amino acid sequence (X1) [D]P[D](X2)[D] (in the se...  
WO/2018/034901A1
Disclosed are methods of making elamipretide (MTP-131), a peptide compound with therapeutic potential for treating various mitochondrial myopathies. The synthesis of the peptide can be achieved via the use of N-carboxyanhydride-modified ...  
WO/2018/004281A3
Disclosed are a tranexamic acid-peptide having a skin whitening effect and skin whitening activity with excellent thermal stability and time stability, which is capable of inducing return to healthy skin and whitening effect through skin...  
WO/2018/031690A1
Compounds and compositions are disclosed in which a Drug Unit is linked to a targeting Ligand Unit through a self-stabilizing Linker Unit from which a drug compound or active drug moiety is released at the targeted site of action. Method...  
WO/2018/028634A1
Salts of compound (I) and pharmaceutically compositions thereof, specially a base addition salt, an acid addition salt of compound (I) and a pharmaceutically composition thereof, future the use of the compound and the pharmaceutical comp...  
WO/2018/024645A1
The present invention relates to a process for preparation of Carfilzomib of formula (I).  
WO/2018/018863A1
Disclosed are a mild and efficient preparation method for an α-acyloxy alkenyl amide compound and a use thereof in the synthesis of an amide and a polypeptide. The α-acyloxy alkenyl amide compound is obtained by an addition reaction of...  
WO/2018/022937A1
The present invention provides novel peptide inhibitors of interleukin-23, and related methods of using these peptide inhibitors to treat or prevent a variety of diseases and disorders, including inflammatory bowel disease, Crohn's disea...  
WO/2018/019196A1
A substituted boric acid compound, a pharmaceutical composition comprising same, and an application thereof. The substituted boric acid compound is a compound represented by formula (I), or a crystal form, a pharmaceutically acceptable s...  
WO/2018/022866A1
The present invention provides a compound of formula (I) or a salt thereof and their use as a biomarker in assessing or monitoring kidney function in a subject, determining predisposition to developing reduced kidney function, classifyin...  
WO/2018/023028A1
Disclosed is a rapid, non-invasive and highly specific and sensitive diagnostic assay for the identification of individuals with synucleinopathy and for measuring synucleinopathy progression or status. Test kits for diagnosis of an indiv...  
WO/2018/012901A1
The present invention relates to a pharmaceutical composition for cell protection containing cyclo histidine-proline (cyclo His-Pro, CHP) as an active ingredient. The pharmaceutical composition for cell protection containing cyclo histid...  
WO/2018/006667A1
Disclosed are antihypertensive peptides and antihypertensive proteins and a use thereof. The amino acid sequences of the antihypertensive peptides are respectively TTW, VHW and KAKW, and the amino acid sequences of the antihypertensive p...  
WO/2017/184670A3
Provided are methods for treating Zika virus infections by administering a compound selected from:  
WO/2018/007495A1
The present invention relates to compounds of formula (I) and compositions comprising them for use in enhancing umami taste and/ or saltiness of a food product.  
WO/2018/007496A1
The present invention relates to compounds and compositions for use in enhancing flavor and/or saltiness of a food product. Particularly, the present invention relates to compounds of the general formula I) and compositions comprising them.  
WO/2018/008902A1
The present invention relates to a psoriasis-induced animal model and a use thereof and, more particularly, to: a psoriasis-induced animal model transformed such that a Pellino homolog 1 (Peli1) gene is overexpressed according to the adm...  
WO/2018/000079A1
Novel cyclic peptide GHRP-6 analogs of formula (I): (I) or pharmaceutically acceptable esters or salts thereof, are described. These cyclic peptide GHRP-6 analogs may be used for modulating CD36 activity, for example for the treatment of...  

Matches 301 - 350 out of 17,604